170147-76-9

Basic information

• Product Name: N-BOC-5-HYDROXYINDOLINE
• Synonyms: N-BOC-5-HYDROXYINDOLINE;1H-Indole-1-carboxylicacid,2,3-dihydro-5-hydroxy-,1,1-diMethylethylester;tert-butyl 5-hydroxyindoline-1-carboxylate
• CAS NO: 170147-76-9
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.28
• Mol File: 170147-76-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-BOC-5-HYDROXYINDOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-5-HYDROXYINDOLINE(170147-76-9)
• EPA Substance Registry System: N-BOC-5-HYDROXYINDOLINE(170147-76-9)

Safety Data

• Hazardous Substances Data: 170147-76-9(Hazardous Substances Data)

Usage

General Description

N-BOC-5-HYDROXYINDOLINE is a chemical compound with the molecular formula C14H21NO3. It is a derivative of indoline, which is a heterocyclic compound that contains a six-membered ring with five carbon atoms and one nitrogen atom. N-BOC-5-HYDROXYINDOLINE is often used in organic synthesis and medicinal chemistry as a building block for creating other compounds. Its BOC (tert-butyloxycarbonyl) group makes it a useful precursor for the synthesis of various biologically active molecules, such as pharmaceuticals and natural products. The hydroxy group in its structure also makes N-BOC-5-HYDROXYINDOLINE a potential candidate for the development of novel drug molecules.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 172078-33-0 2,3-Dihydro-1H-indol-5-ol 
• 1215-59-4 5-benzyloxy-1H-indole 
• 170147-29-2 tert-butyl 5-(benzyloxy)-1H-indole-1-carboxylate 
• 273408-46-1 tert-butyl 5-(benzyloxy)indoline-1-carboxylate 
• 226710-84-5 tert-butyl N-(3-phenylthio-3-butenyl)-N-(2-furyl)carbamate 
• 92818-36-5 5-Benzyloxy-2,3-dihydro-1H-indole 

Downstream Products

• 1266116-34-0 5-(trans-4-tert-butyl-cyclohexyloxy)-2,3-dihydro-1H-indole 
• 1266116-37-3 3-tert-butoxycarbonylamino-4-[5-(trans-4-tert-butyl-cyclohexyloxy)-2,3-dihydro-indol-1-yl]-4-oxo-butyric acid tert-butyl ester 
• 1266116-41-9 3-amino-4-[5-(trans-4-tert-butyl-cyclohexyloxy)-2,3-dihydro-indol-1-yl]-4-oxo-butyric acid trifluoroacetate 
• 1266116-46-4 1-[5-(trans-4-tert-butyl-cyclohexyloxy)-2,3-dihydro-indol-1-yl]-2-chloro-ethanone 
• 1266116-47-5 (2-{2-[5-(trans-4-tert-butyl-cyclohexyloxy)-2,3-dihydro-indol-1-yl]-2-oxo-ethylamino}-ethyl)-phosphonic acid diethyl ester 
• 1266116-48-6 (2-{2-[5-(trans-4-tert-butyl-cyclohexyloxy)-2,3-dihydro-indol-1-yl]-2-oxo-ethylamino}-ethyl)-phosphonic acid 
• 1266116-33-9 5-(trans-4-tert-butyl-cyclohexyloxy)-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester 
• 1266120-63-1 5-(4-trifluoromethyl-cyclohexyloxy)-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester 
• 957204-21-6 1-(tert-butoxycarbonyl)-5-[(2-trifluoromethyl-4-biphenyl)methoxy]indoline 
• 957204-27-2 1-(tert-Butoxycarbonyl)-5-(2-nitrobiphenyl-4-ylmethoxy)indoline 
• 957204-14-7 1-(tert-butoxycarbonyl)-5-(2-cyano-4-biphenylmethoxy)indoline 
• 92818-38-7 5-hydroxyindoline hydrochloride 
• 957204-09-0 5-(4-biphenylmethoxy)indoline-1-carboxylic acid tert-butyl ester 
• 957207-11-3 5-(3,4-bistrifluoromethylbenzyloxy)indoline-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Indoline-1-formamide compound as well as preparation method and medical application thereof

The invention relates to a novel indoline-1-formamide compound for regulating or inhibiting the activity of a vascular endothelial growth factor receptor (VEGFR), a preparation method of the compoundand medical application of the compound. Specifically, t

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula ( I ) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention disclo